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Background: The composite summary score (range, 0–24) of abdominal aortic
calciﬁcation (AAC) devised by Kauppila et al is a simple method of assessing AAC
severity. However, few studies have been conducted to determine an optimal AAC
cutoff score for the prediction of mortality or to investigate the relation between
mineral metabolism and AAC progression using the scoring system.
Methods: The medical records of 112 patients on hemodialysis who had undergone
simple lateral lumbar radiography every 6 months from August 2009 were
reviewed. Patients were followed until November 2012, and the relationship
between the degree of AAC at baseline and mortality was evaluated. In addition,
the relationship between the progression of AAC and serum concentrations of
calcium and phosphate was evaluated in the 75 patients who were successfully
followed until November 2012.
Results: The mean AAC score at baseline was 5.574.8, and the cutoff calciﬁcation
score for the prediction of mortality was 7.75 (sensitivity¼61%, speciﬁcity¼81%).
Patients were allocated to Group A (baseline total calciﬁcation score r8.0, n¼85)
or Group B (baseline total calciﬁcation score48.0, n¼27), and multivariate analysis
showed that Group B was an independent risk factor of all-cause mortality and
cardiovascular events. Of the 75 patients successfully followed, 51 showed AAC
progression (Group 1) and 24 showed no change or improvement (Group 2). Group
1 was found to have signiﬁcantly higher mean serum corrected calcium levels
during the 2nd year and 3rd year of follow-up than Group 2. Furthermore, repeated-
measures analysis of variance showed higher monthly corrected calcium concen-
trations (P¼0.099) and mean corrected calcium levels during the 1st year, 2nd year,
and 3rd year of follow-up (P¼0.062) in Group 1, but without statistical signiﬁcance.
The cutoff values of mean corrected calcium of the 2nd year and 3rd year for the
prediction of AAC progression during follow-up years were 8.96 mg/dL and
9.45 mg/dL, respectively. Serum phosphate levels and corrected calciumpho-
sphate values were similar in Groups 1 and 2.
Conclusion: Patients with an AAC score of48 at baseline seem to be at higher risk
of mortality during follow-up. Of the serum variables examined, such as corrected
calcium, phosphate, and corrected calciumphosphate, corrected calcium wasn Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
and Hypertension, Department of Internal Medicine, Inha University College of Medicine, 27 Inhang-ro,
Kidney Res Clin Pract 33 (2014) 95–10296found to be marginally associated with AAC progression. However, a larger-scale
prospective study is required to conﬁrm our ﬁndings.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Arterial calciﬁcation, including aortic calciﬁcation, is highly
prevalent in end-stage renal disease (ESRD) patients, and the
extent of arterial calciﬁcation has been shown to be predictive
of subsequent cardiovascular disease (CVD) and mortality in
these patients [1–5].
Animal experiments suggest that disturbances in mineral
metabolism play a major role in the initiation and progression
of medial wall calciﬁcation [6,7]. Human studies have shown
that, in addition to traditional risk factors, several clinical
factors—such as hypercalcemia, hyperphosphatemia, elevated
calcium (Ca)phosphate (P) product, hyperparathyroidism,
chronic inﬂammation, Ca overload (induced by the use of Ca-
based P binders and vitamin D analogues), higher dialysate Ca
concentration, adynamic bone disease, and old age—are asso-
ciated with the progression of arterial calciﬁcation in ESRD
patients on dialysis [1,8–11].
Hyperphosphatemia is being increasingly recognized as a
major stimulus of vascular calciﬁcation [12]; however, studies
have produced inconsistent results about associations between
hyperphosphatemia and the extent and progression of vascu-
lar calciﬁcation [2]. Furthermore, in one report, it was sug-
gested that arterial calciﬁcation may be a bystander, rather
than the cause of changes in cardiac structure and function
[13,14]. In addition, patients without evidence of arterial
calciﬁcation at presentation are unlikely to develop arterial
calciﬁcation de novo, at least in the short term [15,16].
The composite summary score (range 0–24) of abdominal
aortic calciﬁcation (AAC) devised by Kauppila et al [17] provides a
simple, low-cost means of assessing subclinical vascular disease,
and has been shown to be highly predictive of subsequent
cardiovascular morbidity and mortality in the general population
and hemodialysis (HD) patients [4,5,18]. However, few studies
have sought to determine optimal AAC score cutoff values for the
prediction of mortality or the relation between mineral metabo-
lism and AAC progression using the scoring system.
Accordingly, the aims of this study were to evaluate the
relationship between baseline AAC score and mortality and to
identify an optimum AAC cutoff score for the prediction of
mortality in ESRD patients on HD. In addition, the serum levels
of Ca, P, and Ca P products were monitored during follow-up,
and their relationships with AAC progression were analyzed.Methods
Participants
This retrospective study was performed on ESRD patients on
HD who had been followed up at the outpatient HD clinic of Inha
University Hospital (Incheon, Republic of Korea). A total of 112
ESRD patients on HD at study commencement in September
2009 were included. Patients were followed up until death,kidney transplantation, transfer to other hospital, or until
November 2011. Demographic, clinical, and biochemical data
were collected frommedical records. Comorbidities were assessed
using modiﬁed Charlson comorbidity index (CCI) score [19,20].
HD was performed for 4 hours per session, three times per
week, using a polysulfone dialyzer (F6HPS; Fresenius Medical
Care, Bad Homburg, Germany) and a Fresenius Medical Care
5008 machine. Dialyzers were not reused. Dialysate concen-
trations of sodium, potassium, bicarbonate and calcium were
138 mEq/L, 2.5 mEq/L, 30 mEq/L, and 3.5 mEq/L, respectively,
for nondiabetics, and 140 mEq/L, 2.0 mEq/L, 25 mEq/L, and
2.5 mEq/L, respectively, for diabetics. Blood ﬂow rates were
between 250 mL/minute and 300 mL/minute, depending
on arteriovenous ﬁstula status. The dialysate ﬂow rate was 500
mL/min and Kt/Vurea was calculated using the Daugirdas sec-
ond-generation equation [21].
The study protocol was approved by the Institutional Review
Board of Inha University Hospital and complied with the
Declaration of Helsinki. Written consent forms were not required
because of the retrospective nature of the study. All data used
were obtained routinely for patient management purposes.
Evaluation of abdominal aortic calciﬁcation
Between September 2009 and November 2011, radiographs
of the left lumbar spine were acquired in the standing position
every 6 months. The severity of AAC was graded using the
scoring system devised by Kauppila et al [17].
Calciﬁc deposits in the abdominal aorta adjacent to each
lumbar vertebra from the ﬁrst lumbar vertebrae to the fourth
lumbar vertebrae were assessed separately at baseline for the
anterior and posterior aortic walls. Lesions were graded as
follows: 0, no aortic calciﬁc deposits; 1, small scattered calciﬁc
deposits occupying less than one-third of the longitudinal wall
of the aorta; 2, calciﬁc deposits occupying one-third or more,
but less than two-thirds of the longitudinal wall of the aorta;
and 3, calciﬁc deposits occupying two-thirds or more of the
longitudinal wall of the aorta. Individual level-speciﬁc severity
scores were summarized to yield anterior wall (ScAnt; range
0–12), posterior wall (ScPost; range 0–12), and sum (ScSum;
range 0–24) AAC scores.
AAC scoring was performed using radiographs taken at base-
line and after 3 years by three physicians (HYK, OHL, and MJK)
who were completely unaware of the patient data. Prior to
scoring, the three assessors were trained by a radiologist on how
to perform the scoring until similar scores were achieved. When
the scores of the three assessors differed, mean scores were used.
To decide whether AAC had progressed over the 3-year
study period, the three assessors compared baseline and ﬁnal
X radiographs. Progression of AAC was deﬁned as the occur-
rence of new calciﬁcations or as enlargements of the calciﬁed
area present at baseline. Patients were assigned to Group 1
(exhibit progression; n¼51) or Group 2 (showed no change or
an improvement; n¼24) based on the assessors’ opinions.
Table 1. Baseline patient characteristics
Characteristic Value
n 112
Sex (M/F) 1:1.3
DM (%) 53 (47.3)
Age (y) 59712
HD duration (y) 4.473.6
ESRD duration (y) 6.074.0
aCCI score 3.571.2
BMI (kg/m2) 22.473.3
AAC score (25th, 50th, 75th percentile) 5.574.8 (1.5, 4.5, 8.0)
eCoronary score (median) 138.07167.1 (104.3)
BUN (mg/dL) 69.0718.3
Creatinine (mg/dL) 10.672.7
Albumin (g/dL) 3.770.4
Hb (g/dL) 10.071.2
Total cholesterol (mg/dL) 149733
Triglyceride (mg/dL) 130786
LDL cholesterol (mg/dL) 86725
Ca (mg/dL) 9.270.9
P (mg/dL) 5.171.7
cCa (mg/dL) 9.470.9
cCaP (mg2/dL2) 48.1716.2
iPTH (pg/mL) 141.67187.5
Lipoprotein (a) (mg/dL) (median) 28.1725.3 (17.9)
CRP (mg/dL) (median) 0.4670.97 (0.14)
Kt/Vurea 1.470.2
AAC, abdominal aortic calciﬁcation; aCCI, age-adjusted Charlson comor-
bidity index; BMI, body mass index; BUN, blood urea nitrogen; Ca,
calcium; cCa, corrected calcium; CRP, C-reactive protein; DM, diabetes
mellitus; eCoronary score, estimated coronary calciﬁcation score; ESRD,
end-stage renal disease; Hb, hemoglobin; HD, hemodialysis; iPTH, intact
parathyroid hormone; LDL, low density lipoprotein; P, phosphate.
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the opinions of two agreeing assessors. The percentage of
agreement for progression by three assessors was 84.0%, and
the κ value was 0.749.
Determination of coronary arterial calciﬁcation scores
The following equation developed by Huybrechts et al [22],
which is based on electron-beam tomography ﬁndings, was
used to determine coronary artery calciﬁcation scores (eCor-
onary score):
LogeðeCoronary scoreÞ
¼ Age 0:02þESRD duration
ð436 months¼ 1; r36 months¼ 1Þ  0:35
þcorrected Ca 1:42þP 0:39
þtotal cholesterol ð0:16Þ
þhigh density lipoprotein ðHDLÞ cholesterol ð0:54Þ
þCVD history ð1¼ no; 1¼ yesÞ  ð0:70Þ
þCVD history ð1¼ no; 1¼ yesÞ  age 0:01
To use this equation, corrected Ca, P, total cholesterol, and HDL
cholesterol concentrations were converted into SI units.
Biochemical assays
Routine blood tests were performed monthly. Triglyceride,
HDL cholesterol, low density lipoprotein (LDL) cholesterol,
C-reactive protein (CRP), and intact parathyroid hormone
(iPTH) were measured every 3 months. Corrected Ca (cCa)
levels were calculated using the following formula [23]:
cCa¼ Caþ0:8 ð4serum albuminÞ:
Monthly cCa, P, and cCaP product values during follow-up
period were subjected to analysis.
Statistical analysis
Results are presented as mean 7 standard deviation (SD)
or as medians and ranges. Differences between group means
and median values were evaluated using the unpaired Student
t test and the Mann–Whitney U test. In case of continuous
variables (e.g., Ca, P, iPTH) measured repeatedly during the
follow-up, differences between the groups were analyzed by
repeated-measures analysis of variance. Group categorical data
were compared using the Chi-square test. Receiver operating
characteristic (ROC) curve analysis was used to deﬁne the best
baseline AAC score cutoff value for mortality based on con-
siderations of sensitivity and speciﬁcity—that is, as the value
that maximized the sum of sensitivity and speciﬁcity.
Patients were divided into Group A (baseline AAC scorer
cutoff value; n¼85) or Group B (baseline AAC score4cutoff
value; n¼27). Overall patient survival was estimated using the
Kaplan–Meier method, and outcomes were compared using the
log rank test. The data of patients who underwent kidney
transplantation or were transferred to other hospitals were
censored for patient survival analysis. The primary outcome was
all-cause mortality, and the secondary outcome was CVD events
(fatal and nonfatal). CVD events were deﬁned as death from
cardiovascular causes, nonfatal myocardial infarction, nonfatal
stroke, therapeutic coronary procedure (coronary artery bypass
graft, percutaneous transluminal coronary angioplasty, and/or
stenting), therapeutic carotid procedure (endarterectomy and/or
stenting), vascular intervention (revascularization, percutaneoustransluminal angioplasty, and/or stenting), or amputation. Patients
who stopped receiving HD at our hospital due to kidney trans-
plantation or moved to another hospital were not followed to
determine primary or secondary outcomes, which were analyzed
using Cox’s multivariate proportional hazard models that included
all signiﬁcant variables identiﬁed by univariate analysis.
Patients who completed the study period were allocated
based on AAC progression to Group 1 or Group 2 as described
above. These two groups were compared with respect to baseline
characteristics, serum Ca, P, and cCaP product levels during the
follow-up. A p value of o0.05 was considered signiﬁcant.Results
Abdominal aortic calciﬁcation at baseline and mortality
Table 1 lists the baseline characteristics of the 112 partici-
pants. The mean overall patient age was 59712 years, and the
male/female ratio was 1:1.3. Fifty-three patients (47.3%) were
diabetics. Previous mean durations of ESRD and HD were
6.074.0 years and 4.473.6 years, respectively. The mean
age-adjusted CCI (aCCI) score at baseline was 3.571.2, the
mean BMI was 22.473.3 kg/m2, and the mean eCoronary
score was 138.07167.1 (median value 104.3). Mean hemoglobin,
blood urea nitrogen, serum creatinine, albumin, total cholesterol,
triglyceride, LDL cholesterol, HDL cholesterol, lipoprotein (a),
Ca, cCa, P, cCaP, and iPTH concentrations were 10.071.2 g/dL,
69.0718.3 mg/dL, 10.672.7 mg/dL, 3.770.4 g/dL, 1497
33mg/dL, 130786mg/dL, 86725mg/dL, 39712mg/dL, 28.17
25.3 mg/dL, 9.270.9 mg/dL, 9.470.9 mg/dL, 5.171.7 mg/dL,
48.1716.2 mg2/dL2, and 141.67187.5 pg/mL, respectively. The
mean Kt/Vurea was 1.470.2, the mean ScSum AAC score was
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percentile values of ScSum AAC score were 1.5, 4.5 and 8.0,
respectively.
The mean follow-up duration was 32.8712.2 months
(range 3–46 months). During the follow-up period, 18 (16.1%)
patients died (5 of cardiovascular causes). Twenty-one patients
experienced nonfatal CVD events. Sixteen patients were trans-
ferred to other hospitals. Three patients underwent kidney
transplantation, and two patients were lost during follow-up.
The 3-year survival rate was 84.0%.
The ROC curve analysis of baseline AAC score, with respect to
mortality, revealed an area under the ROC curve of 0.681 [95%Figure 1. Receiver operating characteristic (ROC) curve analysis of
baseline abdominal aortic calciﬁcation (AAC) score for the mortality.
Area under the ROC curve is 0.681 (95% conﬁdence interval, 0.517–
0.845, P¼0.015). The cutoff value of AAC score is 7.75 (sensitivity¼ 61%,
speciﬁcity¼81%).
Table 2. Comparison of characteristics between two groups according t
Group A
AAC score r8
(n¼85)
Age (y) 57713
Male (%) 33 (38.8)
DM (%) 33 (38.8)
HD duration (y) 3.973.4
ESRD duration (y) 5.473.9
BMI (kg/m2) 22.473.4
aCCI score (median) 3.472.4 (2.5)
eCoronary score (median) 111.871.2 (95.1)
BUN (mg/dL) 70.2718.4
Creatinine (mg/dL) 10.872.8
Kt/Vurea 1.470.2
Albumin (g/dL) 3.870.4
Hb (g/dL) 10.071.3
CRP (mg/dL) 0.3670.59
cCa (mg/dL) 9.370.9
P (mg/dL) 5.371.7
cCaP (mg2/dL2) 48.9716.2
iPTH (pg/mL) (median) 165.87207.1 (82.4)
Total cholesterol (mg/dL) 150732
Triglyceride (mg/dL) 132792
LDL cholesterol (mg/dL) 84725
HDL cholesterol (mg/dL) 39712
Lipoprotein (a) 26.2721.1
aCCI, aged-adjusted Charlson comorbidity index; BMI, body mass index; BU
DM, diabetes mellitus; ESRD, end-stage renal disease; Hb, hemoglobin; HD
hormone; LDL, low density lipoprotein; P, phosphate.conﬁdence interval (CI), 0.517–0.845; P¼0.015]. The optimal cutoff
value of ScSum AAC score was 7.75 (sensitivity¼61%,
speciﬁcity¼81%; Fig. 1). When an AAC score 5 was used as a
cutoff value, the area under the ROC curve was 0.374 (P¼0.092).
Patients were allocated to one of two groups using a cutoff value
of 8; Group A (baseline ScSum AAC score r8.0, n¼85) or Group B
(baseline ScSum AAC score48.0, n¼27). Age, ESRD duration, HD
duration, proportion of patients with diabetes, aCCI score, eCor-
onary score, cCa, CRP, LDL cholesterol, and iPTH concentrations
were all signiﬁcantly higher in Group B (Table 2).
Kaplan–Meier analysis revealed that all-cause mortality was
signiﬁcantly higher in Group B (Fig. 2A; P¼0.001). Group B also
had a signiﬁcantly higher proportion of fatal and nonfatal CVD
events than Group A (Fig. 2B; P ¼0.037). According to multi-
variate analysis, adjusted for aCCI score, ESRD and HD durations,
eCoronary score, CRP, cCa, LDL cholesterol, and iPTH, Group B
was an independent risk factor of all-cause mortality [hazard
ratio (HR), 4.205; 95% CI, 1.658–10.669] (Table 3). Furthermore,
Group B (HR, 1.801; 95% CI 1.281–2.531), eCoronary score (HR,
1.002; 95% CI, 1.001–1.004), and LDL cholesterol (HR, 1.018; 95%
CI, 0.999–1.037) were found to be independent risk factors of
fatal and nonfatal CVD events.
Progression of abdominal aortic calciﬁcation
Of the 112 patients, 75 (67.0%) completed the follow-up
X-ray for 3 years and 37 did not. The causes of incomplete
follow-up were as follows: death (18 patients), kidney trans-
plantation (3 patients), transfer to other hospitals (16
patients), follow-up loss (2 patients), and failure to undergo
a follow-up X-ray at 3 years (1 patient). No differences in
baseline clinical and laboratory characteristics were evident
between the patients who did and did not complete follow-up,
with the exception of age (56711 vs. 66712 years, P o
0.001). Fifty-one of the 75 patients (68.0%) who completedo AAC score
Group B P
AAC score 48
(n¼27)
6679 0.020
15 (55.6) 0.126
20 (74.1) 0.001
6.074.1 0.007
7.674.1 0.013
22.573.0 0.857
12.573.3 (11.5) <0.001
220.57305.7 (143.2) 0.001
65.3717.8 0.229
10.272.4 0.312
1.470.2 0.542
3.770.4 0.253
10.071.1 0.791
0.7571.65 0.058
9.770.8 0.046
4.771.5 0.139
45.8716.4 0.399
65.6760.0 (43.6) 0.001
144737 0.414
125767 0.704
93723 0.070
38713 0.698
34.3735.4 0.268
N, blood urea nitrogen; cCa, corrected calcium; CRP, C-reactive protein;
, hemodialysis; HDL, high density lipoprotein; iPTH, intact parathyroid
Figure 2. Kaplan–Meier curves for (A) all-cause mortality and
(B) fatal and nonfatal events. The linear line denotes patients with
baseline abdominal aortic calciﬁcation (AAC) score r8 and the broken
line denotes patients with baseline AAC score 48.
Table 3. Risk factors for all-cause mortality and fatal and nonfatal
cardiovascular events
HR 95% CI P
Lower Upper
All-cause mortalityn
AAC score 4 8.0† 4.205 1.658 10.669 0.002
Fatal and nonfatal cardiovascular events‡
AAC score 48.0† 1.801 1.281 2.531 0.001
eCoronary score 1.002 1.001 1.004 0.007
LDL cholesterol 1.018 0.999 1.037 0.057
n Adjusted for duration of ESRD and HD, aCCI, eCoronary score, CRP,
cCalcium, iPTH, and LDL cholesterol.
† The reference is patients with AAC score r8.0.
‡ Adjusted for duration of ESRD and HD, aCCI, CRP, cCalcium, and iPTH.
Results shown as HR and 95% CI from Cox proportional hazard models.
AAC, abdominal aortic calciﬁcation; aCCI, age-adjusted Charlson comor-
bidity index; cCalcium, corrected calcium; CI, conﬁdence interval; CRP,
C-reactive protein; eCoronary score, estimated coronary calciﬁcation
score; ESRD, end-stage renal disease; HD, hemodialysis; HR, hazard
ratio; iPTH, intact parathyroid hormone; LDL, low density lipoprotein.
Figure 3. Comparison of mean values of corrected calcium concen-
trations of 3 years between Groups 1 and 2.
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and 24 showed no change or improvement (Group 2). Age, sex
ratio, proportions with diabetes, and durations of ESRD and
HD were not different in these two groups. Furthermore, nointergroup differences were observed in Hb, total cholesterol,
LDL cholesterol, albumin, P, cCaP, and iPTH during follow-
up. cCa concentrations remained constant from baseline to
Month 14 (Fig. 3). However, from 15 months, cCa concentra-
tions were signiﬁcantly higher in Group 1 and remained so
until the end of the follow-up period. Mean cCa concentrations
were similar during the 1st year in Groups 1 and 2. During the
2nd year and 3rd year, Group 1 had signiﬁcantly higher mean
cCa concentrations (Table 4). However, repeated-measures
analysis of variance showed that monthly cCa concentrations
(P¼0.099) and mean cCa concentrations during the 1st year,
2nd year, and 3rd year (P¼0.062) were not signiﬁcantly higher
in Group 1.
In addition, the ROC curve analysis of mean cCa concentrations
versus the progression of AAC revealed areas of 0.583 (95% CI,
0.439–0.727; P¼0.247), 0.690 (95% CI, 0.558–0.822; P¼0.008),
and 0.710 (95% CI, 0.584–0.836; P¼0.004) for mean values during
the 1st year, 2nd year, and 3rd year, respectively. The cutoff values of
mean cCa concentrations during the 2nd year and 3rd year were
8.96mg/dL (sensitivity¼68.6%, speciﬁcity¼70.8%) and 9.45mg/dL
(sensitivity¼49.0%, speciﬁcity¼87.5%), respectively.
In addition, the ROC curve analysis of baseline ScAnt, ScPost,
and ScSum AAC scores for the progression of AAC revealed
areas of 0.643 (95% CI, 0.506–0.780; P¼0.018), 0.679 (95% CI,
0.536–0.823; P¼0.013), and 0.670 (95% CI, 0.532–0.808;
P¼0.018), respectively. The cutoff values of baseline ScAnt,
ScPost, and ScSum scores were 0.75 (sensitivity¼88.2%,
speciﬁcity¼33.3%), 1.25 (sensitivity¼72.5%, speciﬁcity¼66.7%),
and 2.25 (sensitivity¼74.5%, speciﬁcity¼58.3%), respectively.Discussion
In this study, baseline degree of AAC was found to be
associated with all-cause mortality and fatal and nonfatal CVD
events in ESRD patients on HD. The optimum AAC cutoff score
for predicting mortality was found to be 7.75. AAC progression
was found in 68% of patients who had successfully completed
follow-up. Furthermore, patients showing AAC progression
tended to have higher serum cCa concentrations.
As atherosclerosis advances, microcalciﬁcations of subinti-
mal plaque form and increase in size to become visible on
routine radiographs of the thorax and abdomen [18,24], and
thus, provide a means of quantitatively evaluating disease
severity by simple radiography. In a previous study, AAC
assessed by simple lateral abdomen radiography was found
to be highly predictive of subsequent cardiovascular morbidity
Table 4. Comparison of mean values of cCa, P, and cCaP at 1st, 2nd,
and 3rd years between Groups 1 and 2n
Group 1 Group 2 P
(n¼51) (n¼24)
cCa (mg/dL)
1st year 9.170.6 9.070.7 0.302
2nd year 9.270.7 8.870.6 0.015
3rd year 9.370.7 8.970.7 0.018
P (mg/dL)
1st year 5.170.9 5.071.1 0.609
2nd year 5.270.9 4.971.1 0.347
3rd year 5.271.2 5.071.2 0.709
cCaP (mg2/dL2)
1st year 47.079.1 45.1711.7 0.437
2nd year 47.7711.8 43.2710.4 0.113
3rd year 48.2713.6 44.8711.7 0.296
n Group 1, progression of AAC score; Group 2, no progression of AAC
score.
cCa, corrected calcium; P, phosphate.
Kidney Res Clin Pract 33 (2014) 95–102100and mortality [18]. Vascular calciﬁcation, including aortic
calciﬁcation, is highly prevalent in dialysis patients [25,26],
and CVD is the leading cause of death among ESRD patients
[27]. Furthermore, several studies have indicated that arterial
calciﬁcations contribute to the high incidence of cardiovascu-
lar events and mortalities observed in ESRD patients
[2,3,26,28–30]. The results of these studies demonstrate that
scoring based on simple lateral abdominal radiographic ﬁnd-
ings can be used to evaluate AAC and that patients with higher
AAC scores exhibit signiﬁcantly higher mortality and fatal and
nonfatal CVD events. A small number of studies have
attempted to determine optimal AAC score cutoff values for
the prediction of mortality. However, in these previous studies,
patients were classiﬁed based on the presence or absence of
AAC or using tertile of total AAC score [4,5]. The latter study
showed that an AAC score of 5 (lower tertile value of total
score 24) indicated a higher risk of mortality [5], and another
study produced a similar result [31]. In the present study, we
found that the optimum AAC cutoff score for predicting
mortality was 7.75 and that its sensitivity and speciﬁcity were
61% and 81%, respectively. By contrast, an AAC score of 5 was
not found to be statistically signiﬁcant. We are not able to
speculate convincingly as to why an AAC score of 8 is superior
to a score of 5 because of the small-scale and retrospective
nature of the present study. Nevertheless, this cutoff value of
8 could be valuable in clinical practice because it provides a
straightforward means of identifying patients at high risk of
mortality or CVD events.
It is known that, in addition to traditional risk factors,
several clinical factors—such as hypercalcemia, hyperphospha-
temia, an elevated CaP product, hyperparathyroidism,
chronic inﬂammation, Ca overload induced by the use of Ca-
based P binders and vitamin D analogues, a high dialysate Ca
concentration, adynamic bone disease, and old age—are asso-
ciated with the progression of arterial calciﬁcation in ESRD
patients on dialysis [1,2,8–11]. Of these, hyperphosphatemia is
increasingly being mentioned as a major stimulus for vascular
calciﬁcation [12]. However, hypercalcemia and hyperphospha-
temia both appear to have important roles in this context. Ca
accelerates the mineralization of vascular smooth muscle cell
by activating Pit-1 (a type III sodium-dependent P co-trans-
porter) and by increasing the cellular inﬂux of phosphate
[7,32]. Chertow et al [1] reported that Ca-based P binders are
associated with progressive coronary artery and aorticcalciﬁcation, and suggested that Ca might directly or indirectly
adversely inﬂuence the balance of skeletal and extraskeletal
calciﬁcation in HD patients. Yamada et al [33] reported that an
increase in serum Ca after HD was related to the rate of
progression of aortic calciﬁcation, and Noordzij et al [2]
reported that a baseline plasma Ca level of49.5 mg/dL was
associated with the progression of AAC. In the present study,
serum cCa concentration showed an association with the
progression of vascular calciﬁcation rather than hyperpho-
sphatemia or an elevated Ca P product.
When we evaluated mean serum cCa concentrations during
the 3-year study period, it was found that the cutoff value of
mean cCa concentration during the 3rd year for the progression
of AAC was 9.45 mg/dL, which is similar to the result obtained by
Noordzij et al [2]. Furthermore, this cutoff value is similar to the
serum level of cCa recommended by the Kidney Disease Out-
comes Quality Initiative (K/DOQI) guideline for bone metabolism
and disease in chronic kidney disease [34]. The observed
importance of serum cCa concentration, rather than hyperpho-
sphatemia and elevated CaP product in the present study,
seems to be the result of relatively low serum iPTH concentra-
tions in Groups 1 and 2. Interestingly, the cutoff values of ScAnt,
ScPost, and ScSum AAC scores for the prediction of progression
were very low—at 0.75, 1.25, and 2.25, respectively—which
indicates that even the presence of slight AAC seems to progress
in ESRD patients on HD, and suggests the importance of strict Ca
and P control.
This study has several limitations. First, we only investi-
gated the relations between serum cCa, P, and cCaP product
on AAC progression. Furthermore, the intergroup serum cCa
concentration differences did not reach statistical signiﬁcance.
This prevents us from concluding that serum calcium concen-
tration importantly contributes to AAC progression, but never-
theless suggests a possible association between serum cCa
concentrations and AAC progression. Second, we did not
evaluate relations between Ca load, serum vitamin D, and
dialysate Ca concentrations and the progression of AAC. There-
fore, the relation between arterial calciﬁcation and Ca overload
due to the administration of excessive Ca-containing P binders
remains controversial [1,8,35,36]. Third, the retrospective
nature of and the fact that it was conducted at a single dialysis
center introduces the possibility of selection bias with respect
to the evaluation of AAC progression. Finally, the number of
study participants was relatively small.
We conclude that AAC scores evaluated using simple abdo-
men radiographs appear to be associated with mortality and
CVD events in ESRD patients on HD. An optimum AAC cutoff
score of 8 can be used to predict mortality. Furthermore, our
ﬁndings suggest that serum cCa concentration is associated
with the progression of AAC. However, a further larger-scale
study is required with a longer follow-up to conﬁrm our
ﬁndings.Conﬂicts of interest
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